Peripheral Artery Disease Market to Showcase Growth at a Paltry CAGR of 4% During the Study Period (2019-2032) | DelveInsight

The peripheral artery disease market is expected to grow due to the factors such as an increase in the patient population due to a rise in the prevalence of the condition and the expected entry of emerging therapies in the seven major markets

LAS VEGAS, March 29, 2023 /PRNewswire/ -- DelveInsight's Peripheral Artery Disease Market Insights report includes a comprehensive understanding of current treatment practices, peripheral artery disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Peripheral Artery Disease Market Report

• As per DelveInsight analysis, the peripheral artery disease market size in the 7MM was approximately USD 4 billion in 2022.
• According to the assessment done by DelveInsight, the estimated total prevalent peripheral artery disease cases in the 7MM were approximately 17 million in 2022. 
• Leading peripheral artery disease companies such as Ixaka Ltd (formerly Rexgenero), Hemostemix Inc, Lisata Therapeutics, Caladrius Biosciences, Reven Pharmaceuticals, Inc, Helixmith Co., Ltd, and others are developing novel peripheral artery disease drugs that can be available in the peripheral artery disease market in the coming years.
• The promising peripheral artery disease therapies in the pipeline include REX-001, ACP-01, Honedra (LSTA12), RJX (Rejuveinix), Engensis (VM202), and others.

Discover which therapies are expected to grab the major peripheral artery disease market share @ Peripheral Artery Disease Market Report

Peripheral Artery Disease Overview

Peripheral artery disease (PAD) is a common manifestation of lower extremity arterial stenosis that reduces arterial flow. PAD is well known to be associated with increased morbidity and mortality in patients with cardiovascular (CV) disease. Many people with PAD have no symptoms. The most common peripheral artery disease symptom of the lower extremity is painful muscle cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. On the other hand, those who experience a painful ache in their legs while walking usually recover after a few minutes of rest. This is referred to as "intermittent claudication" in medicine.

PAD symptoms frequently appear gradually over time. PAD is diagnosed through a physical examination of the legs for symptoms such as shiny skin, brittle toenails, hair loss on the legs and feet, and leg ulcers. To diagnose PAD, the ankle-brachial pressure index (ABPI) test is commonly used. When there is doubt about the peripheral artery disease diagnosis, additional testing, such as an ultrasound scan or an angiogram, is performed.

Peripheral Artery Disease Epidemiology Segmentation

DelveInsight estimates that there were approximately 17 million prevalent cases of peripheral artery disease in the 7MM in 2022.

Among the European countries, Germany had the highest diagnosed prevalent population of PAD, followed by Italy in 2022. 

The peripheral artery disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Peripheral Artery Disease Diagnosed Prevalent Cases
• Peripheral Artery Disease Gender-specific Diagnosed Prevalent Cases 
• Peripheral Artery Disease Age-specific Diagnosed Prevalent Cases 
• Peripheral Artery Disease Severity-specific Diagnosed Prevalent Cases 

Download the report to understand which factors are driving peripheral artery disease epidemiology trends @ Peripheral Artery Disease Epidemiological Insights

Peripheral Artery Disease Treatment Market 

The goals of PAD therapy vary according to the severity of the disease. All patients with symptomatic or asymptomatic PAD have a primary concern: lowering the risk of cardiovascular morbidity and mortality. Improving functional status is an additional goal for patients with IC. Finally, preventing leg amputation, restoring mobility, and lowering mortality are critical for CLI patients. Different peripheral artery disease treatment options are available depending on the population and the goal. Tobacco use, diabetes, low-density lipoprotein levels, and hypertension are all considered risk factors that should be managed.

Exercise training, medical therapy, and revascularization are the three primary treatment options for improving functional status in patients with intermittent claudication. Several drugs have been approved for the treatment of IC, including naftidrofuryl oxalate, a 5-hydroxytryptamine type 2 antagonist; cilostazol, a phosphodiesterase III inhibitor; pentoxifylline, a vasodilator; and inositol nicotinate, a vasodilator. All have randomized controlled evidence of some improvement in walking distance.

Carnitine and propionyl-L-carnitine, which interact with skeletal muscle oxidative metabolism, are two other medications that have been shown to improve treadmill walking distance in claudicants. A meta-analysis of iloprost, a prostacyclin analog, revealed reduced death and major amputation at 6 months. Due to the low overall risk of limb-threatening ischemia, people with IC have traditionally been treated conservatively for their leg symptoms with medication therapy, lifestyle changes, and exercise regimens.

To know more about peripheral artery disease treatment guidelines, visit @ Peripheral Artery Disease Management 

Peripheral Artery Disease Pipeline Therapies and Key Companies

• REX-001: Ixaka Ltd (formerly Rexgenero)
• ACP-01: Hemostemix Inc.
• Honedra (LSTA12): Lisata Therapeutics/ Caladrius Biosciences
• RJX (Rejuveinix): Reven Pharmaceuticals, Inc.
• Engensis (VM202): Helixmith Co., Ltd.

Learn more about the FDA-approved drugs for peripheral artery disease @ Drugs for Peripheral Artery Disease Treatment 

Peripheral Artery Disease Market Dynamics

The dynamics of the peripheral artery disease market is expected to change in the coming years. The rising prevalence of PAD due to an aging population, combined with the continued rise in diabetes prevalence, is expected to propel the peripheral artery disease market in the future, creating opportunities for new pharma players. New technologies and advancements in existing therapies are expected to improve endovascular therapy outcomes during the forecast period.

Moreover, several regenerative therapies, including angiogenic recombinant proteins, gene therapy, cell-based therapies (including stem or progenitor cells), and chemokines, have been tested in patients with PAD and nonrevascularizable CLI. Collategene (HGF plasmid) is the only gene therapy approved in Japan. The company also plans to enter the US peripheral artery disease market. Aside from that, many cell therapies are in development. Many cell therapies are being developed to target populations that are not candidates for revascularization or had poor outcomes after revascularization. Thus, the abovementioned factors will boost the peripheral artery disease market in the coming years.

However, some factors will likely impede the growth of the peripheral artery disease market. Despite a strong emerging pipeline, there are not enough late-stage products. The poor prognosis and misdiagnosis are additional  impeding factors which restrains the market from reaching its potential. 

Scope of the Peripheral Artery Disease Market Report

• Therapeutic Assessment: Peripheral Artery Disease current marketed and emerging therapies
• Peripheral Artery Disease Market Dynamics: Attribute Analysis of Emerging Peripheral Artery Disease Drugs 
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Peripheral Artery Disease Market Access and Reimbursement

Discover more about peripheral artery disease drugs in development @ Peripheral Artery Disease Clinical Trials

Table of Contents

Related Reports

Peripheral Arterial Disease Pipeline

Peripheral Arterial Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peripheral arterial disease companies, including Caladrius Biosciences, Reven Pharmaceuticals, Inc, Helixmith Co., Ltd, among others.

Peripheral Artery Disease Epidemiology Forecast

Peripheral Artery Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted peripheral artery disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Critical Limb Ischemia Pipeline

Critical Limb Ischemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key critical limb ischemia companies, including Pluristem Therapeutics, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, among others.

Critical Limb Ischemia Market

Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key critical limb ischemia companies, including Boston Scientific Corporation, AnGes, Inc, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, among others.

Critical Limb Ischemia Epidemiology

Critical Limb Ischemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted critical limb ischemia epidemiology in the 7MM.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs

Heart Failure Market

Upcoming Cardiovascular Diseases Drugs

Key Companies in the Cardiology Segment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo:https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg